Items Tagged ‘secondary malignancy’

March 28th, 2017

FDA Expands Indication for Revlimid® as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Stem Cell Transplant

By

The U.S. Food and Drug Administration (FDA) expanded the existing indication for Revlimid® (lenalidomide) to include use for patients with multiple myeloma as maintenance therapy following autologous stem cell transplant (ASCT). The expanded indication makes Revlimid® the first and only treatment to receive FDA approval for maintenance use following auto-HSCT.1 Autologous stem cell transplant after […]

View full entry

Tags: maintenance, Multiple Myeloma, News, revlimid, secondary cancer, secondary malignancy